Phibro Animal Health Corporation (PAHC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 18/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.89% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- What Is Drawing Attention To Phibro Animal Health (PAHC) Today?
- Is it the Right Time to Add Phibro Stock to Your Portfolio?
- PAHC vs. HAE: Which Stock Is the Better Value Option?
- Reasons to Add STE Stock to Your Portfolio Right Now
- Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
- Is it Apt to Retain Medtronic Stock in Your Portfolio Now?
- Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
- Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Increased dietary calcium inclusion in fully acidified prepartum diets improved postpartum uterine health and fertility when fed to Holstein cows. — Theriogenology 2020 Jan 15 PMID 31711709
- Effects of an immunomodulatory feed additive on intramammary infection prevalence and somatic cell counts in a dairy herd experiencing major health issues. — Res Vet Sci 2019 Jun PMID 30909121
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Phibro Animal Health Corporation.
Full PAHC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.